CORVEL Q1 FY27 earnings call CRVL

Michael Combs transitioned to Executive Chairman, and Sarah Scott was appointed President and CEO, following more than 18 months of deliberate succession planning. This leadership change is expected to provide continuity and a strong foundation for CorVel's next phase of growth, leveraging Sarah's deep understanding of the business, customers, and culture.

CorVel highlighted its integrated operating model, CorVel Connected, which unifies workflow and data across claims management, clinical services, pharmacy, bill review, provider networks, and ancillary care. This approach allows the company to apply intelligence across the broader claim lifecycle, differentiating it in a market characterized by increasing claim complexity, medical cost inflation, and evolving regulatory environments.

The company is expanding artificial intelligence and automation across selected claims and clinical workflows, including claim summarization, risk identification, and clinical decision support. These tools are designed to promote earlier intervention, greater consistency, and improved productivity. CorVel is standardizing how it measures adoption, operational impact, and client value to guide continued development and investments.

CorVel launched Executive Advisory Services, which assists clients in evaluating their workers' compensation and liability programs through operational expertise, benchmarking, analytics, and technology. Additionally, a new data-driven medical bill repricing capability was introduced to complement existing bill review and network solutions, aiming to support more informed reimbursement decisions and improve cost containment results.

In the group health market, CorVel's CERIS product is expanding its capabilities and developing solutions tailored for specialized claims segments, addressing cost pressure, margin compression, and increasing regulatory requirements. The company sees meaningful longer-term opportunities to apply CERIS' commercial payment integrity expertise within selected government health care programs, evaluating expansion based on market demand and potential return.

CorVel maintains a strong financial position, reporting a cash balance of $256 million and a debt-free balance sheet. The company continues to fund its share repurchase program from strong operating cash flow, having repurchased 377,098 shares for $21.8 million during the quarter. Since inception, the program has repurchased 70% of total shares outstanding at an average price of $7.87 per share.